HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-542X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women ; volume:20 ; number:1 ; day:20 ; month:11 ; year:2018 ; pages:1-15 ; date:12.2018
Breast cancer research ; 20, Heft 1 (20.11.2018), 1-15, 12.2018
- Creator
-
Wege, Anja Kathrin
Chittka, Dominik
Buchholz, Stefan
Klinkhammer-Schalke, Monika
Diermeier-Daucher, Simone
Zeman, Florian
Ortmann, Olaf
Brockhoff, Gero
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13058-018-1072-1
- URN
-
urn:nbn:de:101:1-2019010400305914901285
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:52 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wege, Anja Kathrin
- Chittka, Dominik
- Buchholz, Stefan
- Klinkhammer-Schalke, Monika
- Diermeier-Daucher, Simone
- Zeman, Florian
- Ortmann, Olaf
- Brockhoff, Gero
- SpringerLink (Online service)
Other Objects (12)
Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer
Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells
Targeting c-Jun inhibits fatty acid oxidation to overcome tamoxifen resistance in estrogen receptor-positive breast cancer
Sex-steroid hormones and risk of postmenopausal estrogen receptor-positive breast cancer: a case–cohort analysis
BreastDefend enhances effect of tamoxifen in estrogen receptor-positive human breast cancer in vitro and in vivo
CYP27A1 expression is associated with risk of late lethal estrogen receptor-positive breast cancer in postmenopausal patients
Small molecule inhibitor targeting the Hsp70-Bim protein–protein interaction in estrogen receptor-positive breast cancer overcomes tamoxifen resistance
Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer
Molecular markers associated with the outcome of tamoxifen treatment in estrogen receptor-positive breast cancer patients: scoping review and in silico analysis
Local estrogen axis in the human bone microenvironment regulates estrogen receptor-positive breast cancer cells
The impact of CBP expression in estrogen receptor-positive breast cancer
Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer
Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells
Targeting c-Jun inhibits fatty acid oxidation to overcome tamoxifen resistance in estrogen receptor-positive breast cancer
Sex-steroid hormones and risk of postmenopausal estrogen receptor-positive breast cancer: a case–cohort analysis
BreastDefend enhances effect of tamoxifen in estrogen receptor-positive human breast cancer in vitro and in vivo
CYP27A1 expression is associated with risk of late lethal estrogen receptor-positive breast cancer in postmenopausal patients
Small molecule inhibitor targeting the Hsp70-Bim protein–protein interaction in estrogen receptor-positive breast cancer overcomes tamoxifen resistance
Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer
Molecular markers associated with the outcome of tamoxifen treatment in estrogen receptor-positive breast cancer patients: scoping review and in silico analysis
Local estrogen axis in the human bone microenvironment regulates estrogen receptor-positive breast cancer cells
The impact of CBP expression in estrogen receptor-positive breast cancer
Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer
Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells
Targeting c-Jun inhibits fatty acid oxidation to overcome tamoxifen resistance in estrogen receptor-positive breast cancer
Sex-steroid hormones and risk of postmenopausal estrogen receptor-positive breast cancer: a case–cohort analysis
BreastDefend enhances effect of tamoxifen in estrogen receptor-positive human breast cancer in vitro and in vivo
CYP27A1 expression is associated with risk of late lethal estrogen receptor-positive breast cancer in postmenopausal patients
Small molecule inhibitor targeting the Hsp70-Bim protein–protein interaction in estrogen receptor-positive breast cancer overcomes tamoxifen resistance
Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer
Molecular markers associated with the outcome of tamoxifen treatment in estrogen receptor-positive breast cancer patients: scoping review and in silico analysis
Local estrogen axis in the human bone microenvironment regulates estrogen receptor-positive breast cancer cells